Pharmacokinetic and pharmacodynamic properties of once‐weekly insulin icodec in individuals with type 2 diabetes
Diabetes, Obesity and Metabolism · 2023-12 · 25 (12) · 3716-3723
DOI: 10.1111/dom.15266 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 11.09.2023. Verfasst von Thomas R Pieber und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Austria. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novo Nordisk.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
To characterize the pharmacokinetic and pharmacodynamic properties of once‐weekly insulin icodec in type 2 diabetes (T2D). Materials and Methods In an open‐label trial, 46 individuals with T2D (18‐75 years; body mass index 18.0‐38.0 kg/m 2 ; glycated haemoglobin ≤75 mmol/mol [≤9%]; basal insulin‐treated) received subcutaneous once‐weekly icodec for ≥8 weeks at individualized doses, aiming at a pre‐breakfast plasma glucose concentration of 4.4 to 7.0 mmol/L (80‐126 mg/dL) on the last three mornings of each weekly dosing interval. Frequent blood sampling to assess total serum icodec concentration (ie, albumin‐bound and unbound) occurred from first icodec dose until 35 days after last dose. Icodec trough concentrations following initiation of once‐weekly dosing were predicted by pharmacokinetic modelling. During the final 3 weeks of icodec treatment, while at steady state, the icodec glucose‐lowering effect was assessed in three glucose clamps (target 7.5 mmol/L [135 mg/dL]): 0 to 36, 40 to 64 and 144 to 168 h post‐dose, thus covering the initial, middle and last part of the 1‐week dosing interval. Glucose‐lowering effect during a complete dosing interval was predicted by pharmacokinetic‐pharmacodynamic modelling.
Results
Model‐predicted icodec steady state was attained after 3 to 4 weeks. At steady state, model‐predicted daily proportions of glucose‐lowering effect on days 1 to 7 of the 1‐week dosing interval were 14.1%, 16.1%, 15.8%, 15.0%, 14.0%, 13.0% and 12.0%, respectively. Icodec duration of action was at least 1 week in all participants. Once‐weekly icodec was overall safe and well tolerated in the current trial.
Conclusions
The pharmacokinetic and pharmacodynamic characteristics of icodec in individuals with T2D support its potential as a once‐weekly basal insulin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Austria.
- Novo Nordisk, Søborg, Denmark.
- Novo Nordisk, Aalborg, Denmark.
ORCID-Profile: Thomas R Pieber
Förderung
- Novo Nordisk
Zitieren
APA
Pieber, T. R., Asong, M., Fluhr, G., Höller, V., Kristensen, N. R., Larsen, J. H., Ribel-Madsen, R., Svehlikova, E., Vinther, S., Voortman, M., & Haahr, H. (2023). Pharmacokinetic and pharmacodynamic properties of once‐weekly insulin icodec in individuals with type 2 diabetes. Diabetes, Obesity and Metabolism, 25(12), 3716-3723. https://doi.org/10.1111/dom.15266
Vancouver
Pieber TR, Asong M, Fluhr G, Höller V, Kristensen NR, Larsen JH, et al. Pharmacokinetic and pharmacodynamic properties of once‐weekly insulin icodec in individuals with type 2 diabetes. Diabetes, Obesity and Metabolism. 2023;25(12):3716-3723. doi:10.1111/dom.15266
BibTeX
@article{Pieber2023,
author = {Pieber, Thomas R and Asong, Marisse and Fluhr, Gabriele and Höller, Vera and Kristensen, Niels R and Larsen, Jonas H and Ribel-Madsen, Rasmus and Svehlikova, Eva and Vinther, Siri and Voortman, Margarete and Haahr, Hanne},
title = {Pharmacokinetic and pharmacodynamic properties of once‐weekly insulin icodec in individuals with type 2 diabetes},
journal = {Diabetes, Obesity and Metabolism},
year = {2023},
volume = {25},
number = {12},
pages = {3716--3723},
doi = {10.1111/dom.15266}
}
EUVIMED